HHM Wealth Advisors’s Celldex Therapeutics CLDX Stock Holding History

HHM Wealth Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-20	Closed	–	–	506
2020 Q2	$0	Hold	20	–	–	﹤0.01%	490
2020 Q1	$0	Buy	+20	New	+$45	﹤0.01%	462

Other funds holding CLDX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

HHM Wealth Advisors's CLDX Position: Q3 2020 in Review

HHM Wealth Advisors sold out of Celldex Therapeutics (CLDX) in Q3 2020, closing a stake of 20 shares.

HHM Wealth Advisors first reported a position in CLDX in Q1 2020 and held it in 2 quarters. The position peaked at $0 in Q2 2020. 91 funds tracked by Wall St. Rank hold CLDX as of Q3 2020.

HHM Wealth Advisors reported no remaining Celldex Therapeutics position as of Q3 2020 after selling out during the quarter.
HHM Wealth Advisors sold 20 Celldex Therapeutics shares in Q3 2020.
HHM Wealth Advisors first reported a position in Celldex Therapeutics in Q1 2020 and held it in 2 quarters.
HHM Wealth Advisors's Celldex Therapeutics position peaked at $0 in Q2 2020.
91 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2020.

Based on HHM Wealth Advisors's 13F filing for Q3 2020, filed 12 Nov 2020.